secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bone Biologics Corp (BBLG)
CIK:        0001419554
Form:       8-K
Filed at:   2024-06-20T23:59:59+00:00
Accession:  0001493152-24-024426
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

First two patients treated in pilot study of NB1 bone graft device for spine fusion
--------------------------------------------------------------------------------

- Two patients treated in Australia in multicenter pilot study evaluating NB1 (NELL-1+DBM) for TLIF in degenerative disc disease.
- Study targets 30 adult subjects; design reviewed by FDA Division of Orthopedic Devices to support US pivotal trial.
- Preclinical studies showed strong safety profile and fusion success; CEO cites $3 billion global spine fusion market opportunity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419554/000149315224024426/0001493152-24-024426-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419554/000149315224024426/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-024426

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer